Nelfinavir mesylate (Q34181862)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Nelfinavir mesylate	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

Nelfinavir mesylate (English)

1 reference

Europe PubMed Central

31 July 2017

1 reference

based on heuristic

inferred from title

author name string

Tebas P

1

1 reference

Europe PubMed Central

31 July 2017

Powderly WG

2

1 reference

Europe PubMed Central

31 July 2017

language of work or name

0 references

publication date

1 December 2000

1 reference

Europe PubMed Central

31 July 2017

Expert Opinion on Pharmacotherapy

1 reference

Europe PubMed Central

31 July 2017

1

1 reference

Europe PubMed Central

31 July 2017

7

1 reference

Europe PubMed Central

31 July 2017

1429-1440

1 reference

Europe PubMed Central

31 July 2017

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1429

21 January 2018

Response to ‘Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy’ by Drs Weil and Lenhard

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1429

21 January 2018

Rational design of peptide-based HIV proteinase inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1429

21 January 2018

Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1429

21 January 2018

Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1429

21 January 2018

A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1429

21 January 2018

A randomized, comparative study of lamivudine plus stavudine, with indinavir or nelfinavir, in treatment-experienced HIV-infected patients

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1429

21 January 2018

Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1429

21 January 2018

BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1429

21 January 2018

In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1429

21 January 2018

A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1429

21 January 2018

Identifiers

10.1517/14656566.1.7.1429

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34181862&oldid=1982110476"